Fig. 1 · Structure

Documents & Downloads

FLI-06

Cat. No. A13815 CAS 313967-18-9

Gamma-secretase inhibitor

FLI-06 is a Notch inhibitor and the early secretory pathway inhibitor. FLI-06 disrupts the Golgi apparatus in a manner distinct from that of brefeldin A and golgicide A.

In Stock

Publications for FLI-06

1 publication citing this product

  1. Tan YJ, .et al. , Future Med Chem, 2018, Sep 1;10(17):2039-2057 PMID: 30066578

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

FLI-06 interferes with early secretory transport. In HeLa reporter assays, it inhibited surface delivery of a GPI-anchored protein and suppressed VSVG-EGFP concentration at ER exit sites even without pretreatment. These cellular experiments support a trafficking-inhibition mechanism; they do not identify a direct molecular target. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Notch EC50 2.3 μM

Cellular Effect

Cell Line Activity Value Description Reference
HCT-116 IC50 1.8 μM Antiproliferative activity against human HCT116 cells after 72 hrs by SYBR green dye based fluorescence assay [PMID: 30201292]
HeLa IC50 2.3 μM Inhibition of gamma secretase mediated Notch delta E activation in human HeLa cells expressing EGFP after 16 hrs by immunofluorescence analysis [PMID: 27045975]

FLI-06 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of FLI-06 from 2 published references. In vitro models include HeLa cells transiently expressing YFP-GPI; human CAL-27 tongue squamous carcinoma cells.

FLI-06 In Vitro Studies

In CAL-27 tongue carcinoma cells, FLI-06 reduced CCK8 viability in a concentration-dependent manner. The reported approximate IC50 range was 4.24–5.26 µM across 48- and 72-hour exposures; the source does not assign the individual values to each time point in its text. This viability endpoint does not establish Notch-specific cytotoxicity. [2]

Inhibition of GPI-anchored reporter transport

Cell-based study · HeLa cells transiently expressing YFP-GPI [1]

FLI-06 inhibited surface transport of the GPI-anchored reporter relative to DMSO. Brefeldin A provided a secretion-blocking comparator.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Surface transport of YFP-GPIQualitative inhibition Inhibited relative to DMSO; >250 cells/condition, three independent experiments[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
18 h
Method
Immunofluorescence microscopy after compound exposure and fixation
Vehicle
DMSO control
Reported limits
Vehicle percentage and full main-text cell-handling methods were not retrieved.
Methods and source locations

Compound reported in the paper: FLI-06; Compound label in the paper: FLI-06 (1)

Evidence concerns the paper’s tested FLI-06 material; it does not validate an Adooq lot or establish equivalence of stereochemical composition.

Supplementary Figure 10a and caption, PDF p. 11; Table 4, p. 21; Supplementary Notes/Table 5, p. 22

Surface transport of YFP-GPI: Immunofluorescence microscopy — Supplementary Figure 10a and caption, PDF p. 11

Rapid inhibition of cargo concentration at ER exit sites

Cell-based study · HeLa cells transiently expressing VSVG-EGFP, analyzed under a temperature-shift transport assay with nocodazole [1]

FLI-06 suppressed cargo concentration and subsequent ER export even when introduced only at the start of the chase. This supports rapid interference with the early secretory pathway.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Concentration of VSVG-EGFP at ER exit sites and subsequent ER exportQualitative fluorescence-pattern response Inhibited even without preincubation; n=3 independent experiments; error bars SEM[1]

Literature-Reported Treatment Conditions

Exposure duration
Chase endpoints 0, 30 and 85 min; pretreatment 30 min, 10 min, or none
Method
Fluorescence microscopy; variance of pixel fluorescence intensity in regions of interest
Vehicle
DMSO control
Reported limits
FLI-06 concentration is not stated in the Figure 11 caption; main-text methods were not retrieved. No concentration is borrowed from Figure 10.
Methods and source locations

Compound reported in the paper: FLI-06; Compound label in the paper: FLI-06 (1)

Evidence concerns the paper’s tested FLI-06 material; it does not validate an Adooq lot or establish equivalence of stereochemical composition.

Supplementary Figure 11 and caption, PDF p. 12; Table 4, p. 21; Supplementary Notes/Table 5, p. 22

Concentration of VSVG-EGFP at ER exit sites and subsequent ER export: Variance of pixel fluorescence intensity; at least 15 cells/condition/experiment — Supplementary Figure 11 and caption, PDF p. 12

CAL-27 concentration-response viability assay

Cell-based study · Human CAL-27 tongue squamous carcinoma cells [2]

CCK8 assays showed a concentration-dependent response after 48 or 72 h. The authors report an approximate CAL-27 IC50 range across these time points.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CAL-27 viability after 48 or 72 hIC50 approximately 4.24~5.26 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
2–10 µM shown in Figure 2A
Exposure duration
48 or 72 h
Method
CCK8 cell viability assay
Reported limits
Cellular vehicle concentration and per-time-point fitted IC50 values are not supplied in the adopted text; no fitted values are inferred from curves.
Methods and source locations

Compound reported in the paper: FLI-06; Compound label in the paper: FLI-06

Evidence concerns the paper’s tested FLI-06 material; it does not validate an Adooq lot or establish equivalence of stereochemical composition.

Results: The Notch Signaling Pathway Inhibitor Restrains Tongue Cancer Cell Proliferation In Vitro; Figure 2A and caption; Methods: Cell Lines And Cell Cultures, Cell Proliferation Assay

CAL-27 viability after 48 or 72 h: CCK8; reported range across two time points, not a treatment dose — Results: The Notch Signaling Pathway Inhibitor Restrains Tongue Cancer Cell Proliferation In Vitro, paragraph 1; Figure 2A

FLI-06 In Vivo Studies

In a CAL-27 xenograft model in female BALB/c nude mice, intraperitoneal FLI-06 at 40 mg/kg during the reported two-cycle regimen reduced tumor volume and endpoint tumor weight compared with saline and DMSO controls (five mice/group). Body weight did not differ significantly among groups. This single xenograft experiment does not establish general tolerability or clinical efficacy. [2]

CAL-27 xenograft tumor response

Animal study · Female BALB/c nude mice, 6–8 weeks old, bearing CAL-27 xenografts; randomized into three groups, five mice/group [2]

FLI-06 treatment reduced tumor volume and endpoint tumor weight relative to saline and DMSO controls; body weight did not differ significantly among groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume, endpoint tumor weight and body weightQualitative comparison Tumor volume and weight decreased; no significant body-weight change[2]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Daily during treatment periods
Treatment course
Started four days after CAL-27 inoculation; administration for six days followed by two days withdrawal, for two cycles. Authors state sacrifice two days after drug withdrawal.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
FLI-06 versus saline and DMSO controls
40 mg/kg body weight
Normal saline control and DMSO control; five mice per groupFLI-06 treatment reduced tumor volume and endpoint tumor weight relative to saline and DMSO controls; body weight did not differ significantly among groups.[2]
FLI-06 versus saline and DMSO controls
Model: Female BALB/c nude mice, 6–8 weeks old, bearing CAL-27 xenografts; randomized into three groups, five mice/group
Reported limits: The FLI-06 dosing formulation, DMSO percentage and injection volume were not specified in the reviewed text. Figure 4 error-bar semantics are not identified in its caption.
Methods and source locations

Compound reported in the paper: FLI-06; Compound label in the paper: FLI-06

Evidence concerns the paper’s tested FLI-06 material; it does not validate an Adooq lot or establish equivalence of stereochemical composition.

Methods: Establishing A Xenograft Tumor Model; Results: FLI-06 Restrains Tumor Growth In The Xenograft Cancer Model; Figure 4A–D and caption

Tumor volume, endpoint tumor weight and body weight: Serial tumor and body-weight measurements; endpoint tumor weighing — Figure 4A–D and caption; corresponding Results paragraph

FLI-06 versus saline and DMSO controls · Methods: Establishing A Xenograft Tumor Model; Results: FLI-06 Restrains Tumor Growth In The Xenograft Cancer Model; Figure 4A–D and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 313967-18-9
Applications Gamma-secretase inhibitor
Formula C25H30N2O5
Molecular Weight 438.52
SMILES
CC1=C(C(C2=C(N1)CC(CC2=O)(C)C)C3=CC=C(C=C3)[N+](=O)[O-])C(=O)OC4CCCCC4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 80 mg/mL (182.43 mM)
Water Insoluble
Ethanol 7 mg/mL (15.96 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

FLI-06 Research References

  1. [1] Krämer A, Mentrup T, Kleizen B, et al. Small molecules intercept Notch signaling and the early secretory pathway. Nature chemical biology (2013). PMID: 24077179 DOI: 10.1038/nchembio.1356 Source material
  2. [2] Gan RH, Lin LS, Xie J, et al. FLI-06 Intercepts Notch Signaling And Suppresses The Proliferation And Self-renewal Of Tongue Cancer Cells. OncoTargets and therapy (2019). PMID: 31571917 DOI: 10.2147/ott.s221231 Source material

Publications

1 publication citing this product

  1. Tan YJ, .et al. , Future Med Chem, 2018, Sep 1;10(17):2039-2057 PMID: 30066578

Added to your cart

View Cart Checkout
Loading...